Sequestering and inhibiting a vascular endothelial growth factor in vivo by systemic administration of a synthetic polymer nanoparticle.
Acrylamides
/ administration & dosage
Angiogenesis Inhibitors
/ administration & dosage
Animals
Antibiotics, Antineoplastic
/ administration & dosage
Cell Line, Tumor
Doxorubicin
/ administration & dosage
Humans
Male
Mice, Inbred BALB C
Nanoparticles
/ administration & dosage
Neoplasms
/ blood supply
Neovascularization, Pathologic
/ drug therapy
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Angiogenesis
Carbohydrate
Heparin-binding domain
Synthetic polymer nanoparticle
Vascular endothelial growth factor
Journal
Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908
Informations de publication
Date de publication:
10 02 2019
10 02 2019
Historique:
received:
09
09
2018
revised:
17
12
2018
accepted:
19
12
2018
pubmed:
24
12
2018
medline:
19
5
2020
entrez:
23
12
2018
Statut:
ppublish
Résumé
Protein affinity reagents (PARs), frequently antibodies, are essential tools for basic research, diagnostics, separations and for clinical applications. However, there is growing concern about the reproducibility, quality and cost of recombinant and animal-derived antibodies. This has prompted the development of alternatives that could offer economic, and time-saving advantages without the use of living organisms. Synthetic copolymer nanoparticles (NPs), engineered with affinity for specific protein targets, are potential alternatives to PARs. Although there are now a number of examples of abiotic protein affinity reagents (APARs), most have been evaluated in vitro limiting a realistic assessment of their potential for more demanding, practical in vivo applications. We demonstrate for the first time that an abiotic copolymer hydrogel nanoparticle (NP1) engineered to bind a key signaling protein, vascular endothelial growth factor (VEGF
Identifiants
pubmed: 30578808
pii: S0168-3659(18)30736-3
doi: 10.1016/j.jconrel.2018.12.033
pii:
doi:
Substances chimiques
Acrylamides
0
Angiogenesis Inhibitors
0
Antibiotics, Antineoplastic
0
Vascular Endothelial Growth Factor A
0
Doxorubicin
80168379AG
N-isopropylacrylamide
B7GFF17L9U
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
13-20Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.